{
    "name": "zoster vaccine recombinant",
    "comment": "Rx",
    "other_names": [
        "Shingrix"
    ],
    "classes": [
        "Vaccines",
        "Inactivated",
        "Viral"
    ],
    "source": "https://reference.medscape.com/drug/shingrix-zoster-vaccine-recombinant-1000163",
    "pregnancy": {
        "common": [
            "There is no available human data to establish vaccine-associated risks with the vaccine in pregnant women"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown whether zoster vaccine is excreted in human milk",
            "Data are not available to assess effects of the zoster vaccine on the breastfed infant or on milk production/excretion"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity (eg, anaphylaxis) to any component of the vaccine"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions; appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration (see Contraindications)",
                "In a postmarketing observational study, an increased risk of Guillain-Barre syndrome was observed during the 42 days following vaccination",
                "Syncope can be associated with injectable vaccine administration; may be accompanied by transient neurological signs (visual disturbance, paresthesia, tonic-clonic limb movements); procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope"
            ],
            "specific": [
                {
                    "type": "Drug interactions overview ",
                    "description": [
                        "Use caution with concomitant use of vaccine administration of zoster recombinant with inactivated influenza",
                        "Immunosuppressive therapies may reduce effectiveness of the zoster vaccine"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, zoster vaccine recombinant.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teplizumab",
            "description": {
                "common": "teplizumab decreases effects of zoster vaccine recombinant by Other (see comment). Avoid or Use Alternate Drug. \nComment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adalimumab",
            "description": {
                "common": "adalimumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alefacept",
            "description": {
                "common": "alefacept decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anakinra",
            "description": {
                "common": "anakinra decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anthrax immune globulin",
            "description": {
                "common": "anthrax immune globulin decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "antithymocyte globulin equine decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "antithymocyte globulin rabbit decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "basiliximab",
            "description": {
                "common": "basiliximab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belimumab",
            "description": {
                "common": "belimumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabazitaxel",
            "description": {
                "common": "cabazitaxel decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "canakinumab",
            "description": {
                "common": "canakinumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "certolizumab pegol decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etanercept",
            "description": {
                "common": "etanercept decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "everolimus",
            "description": {
                "common": "everolimus decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "famciclovir",
            "description": {
                "common": "famciclovir decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "fingolimod decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glatiramer",
            "description": {
                "common": "glatiramer decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "golimumab",
            "description": {
                "common": "golimumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "guselkumab",
            "description": {
                "common": "guselkumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxychloroquine sulfate",
            "description": {
                "common": "hydroxychloroquine sulfate decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "infliximab",
            "description": {
                "common": "infliximab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ixekizumab",
            "description": {
                "common": "ixekizumab decreases effects of zoster vaccine recombinant by pharmacodynamic synergism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leflunomide",
            "description": {
                "common": "leflunomide decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "mercaptopurine decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "muromonab CD3",
            "description": {
                "common": "muromonab CD3 decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "mycophenolate decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "obinutuzumab",
            "description": {
                "common": "obinutuzumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ocrelizumab",
            "description": {
                "common": "ocrelizumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "onasemnogene abeparvovec",
            "description": {
                "common": "onasemnogene abeparvovec decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. When initiating systemic corticosteriod therapy, wait 2 weeks after an inactivated vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pneumococcal vaccine polyvalent",
            "description": {
                "common": "pneumococcal vaccine polyvalent decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Use Caution/Monitor. If possible, complete all age-appropriate vaccinations at least 4 weeks before initiating ponesimod."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilonacept",
            "description": {
                "common": "rilonacept decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab",
            "description": {
                "common": "rituximab, zoster vaccine recombinant. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "rituximab-hyaluronidase, zoster vaccine recombinant. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarilumab",
            "description": {
                "common": "sarilumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "satralizumab",
            "description": {
                "common": "satralizumab decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secukinumab",
            "description": {
                "common": "secukinumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "sirolimus decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "temsirolimus decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "tocilizumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tralokinumab",
            "description": {
                "common": "tralokinumab will decrease the level or effect of zoster vaccine recombinant by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vedolizumab",
            "description": {
                "common": "vedolizumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod decreases effects of zoster vaccine recombinant by immunosuppressive effects; risk of infection. Minor/Significance Unknown. No clinical data are available on the efficacy and safety of vaccinations in patients taking ozanimod. Vaccinations may be less effective if coadministered with ozanimod."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Pain",
            "percent": "88.4"
        },
        {
            "name": "Fatigue",
            "percent": "57"
        },
        {
            "name": "Myalgia",
            "percent": "56.9"
        },
        {
            "name": "Headache",
            "percent": "50.6"
        },
        {
            "name": "Redness",
            "percent": "38.7"
        },
        {
            "name": "Shivering",
            "percent": "35.8"
        },
        {
            "name": "Swelling",
            "percent": "30.5"
        },
        {
            "name": "Fever",
            "percent": "27.8"
        },
        {
            "name": "Gastrointestinal",
            "percent": "24.3"
        },
        {
            "name": "GI",
            "percent": "3"
        },
        {
            "name": "symptoms",
            "percent": "10.3"
        },
        {
            "name": "Pain",
            "percent": "100"
        },
        {
            "name": "Grade",
            "percent": "2.8"
        },
        {
            "name": "Redness",
            "percent": "100"
        },
        {
            "name": "mm",
            "percent": "1.1"
        },
        {
            "name": "Swelling",
            "percent": "82.8"
        },
        {
            "name": "mm",
            "percent": "49"
        },
        {
            "name": "Pain",
            "percent": "45.7"
        },
        {
            "name": "Myalgia",
            "percent": "39.6"
        },
        {
            "name": "Fatigue",
            "percent": "38.4"
        },
        {
            "name": "Headache",
            "percent": "30.3"
        },
        {
            "name": "Redness",
            "percent": "26.5"
        },
        {
            "name": "Shivering",
            "percent": "23.9"
        },
        {
            "name": "Swelling",
            "percent": "16.7"
        },
        {
            "name": "Fever",
            "percent": "69.2"
        },
        {
            "name": "GI symptoms",
            "percent": "35.1"
        },
        {
            "name": "Pain",
            "percent": "36.6"
        },
        {
            "name": "Myalgia",
            "percent": "37.7"
        },
        {
            "name": "Fatigue",
            "percent": "23"
        },
        {
            "name": "Redness",
            "percent": "29"
        },
        {
            "name": "Swelling",
            "percent": "19.5"
        },
        {
            "name": "Headache",
            "percent": "14.3"
        },
        {
            "name": "Shivering",
            "percent": "13.5"
        },
        {
            "name": "Fever",
            "percent": "50"
        },
        {
            "name": "GI symptoms",
            "percent": "74-75"
        },
        {
            "name": "years  Pain",
            "percent": "37-46"
        },
        {
            "name": "Fatigue",
            "percent": "37-43"
        },
        {
            "name": "Myalgia",
            "percent": "21-28"
        },
        {
            "name": "Redness",
            "percent": "15-25"
        },
        {
            "name": "Headache",
            "percent": "11-21"
        },
        {
            "name": "Shivering",
            "percent": "18"
        },
        {
            "name": "GI symptoms",
            "percent": "10-15"
        },
        {
            "name": "Swelling",
            "percent": "6-15"
        },
        {
            "name": "Fever",
            "percent": "74-75"
        },
        {
            "name": "Pain",
            "percent": "37-46"
        },
        {
            "name": "Fatigue",
            "percent": "37-43"
        },
        {
            "name": "Myalgia",
            "percent": "21-28"
        },
        {
            "name": "Redness",
            "percent": "15-25"
        },
        {
            "name": "Headache",
            "percent": "11-21"
        },
        {
            "name": "Shivering",
            "percent": "18"
        },
        {
            "name": "GI symptoms",
            "percent": "10-15"
        },
        {
            "name": "Swelling",
            "percent": "6-15"
        },
        {
            "name": "Fever",
            "percent": "18-49"
        },
        {
            "name": "years Pain",
            "percent": "81-82"
        },
        {
            "name": "Fatigue",
            "percent": "49-51"
        },
        {
            "name": "Myalgia",
            "percent": "41-51"
        },
        {
            "name": "Fever",
            "percent": "9-28"
        },
        {
            "name": "Headache",
            "percent": "23-38"
        },
        {
            "name": "Shivering",
            "percent": "20-26"
        },
        {
            "name": "Redness",
            "percent": "20-25"
        },
        {
            "name": "Swelling",
            "percent": "14-17"
        },
        {
            "name": "GI symptoms",
            "percent": "13-14"
        },
        {
            "name": "Pain",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "11"
        },
        {
            "name": "Pain",
            "percent": "81-82"
        },
        {
            "name": "Fatigue",
            "percent": "49-51"
        },
        {
            "name": "Myalgia",
            "percent": "41-51"
        },
        {
            "name": "Fever",
            "percent": "9-28"
        },
        {
            "name": "Headache",
            "percent": "23-38"
        },
        {
            "name": "Shivering",
            "percent": "20-26"
        },
        {
            "name": "Redness",
            "percent": "20-25"
        },
        {
            "name": "Swelling",
            "percent": "14-17"
        },
        {
            "name": "GI symptoms",
            "percent": "13-14"
        },
        {
            "name": "Pain",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "11"
        },
        {
            "name": "Myalgia",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "8.9"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "8.5"
        },
        {
            "name": "Shivering",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "6.8"
        },
        {
            "name": "Headache",
            "percent": "6"
        },
        {
            "name": "Redness",
            "percent": "100"
        },
        {
            "name": "mm",
            "percent": "2.8"
        },
        {
            "name": "GI symptoms",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "2.1"
        },
        {
            "name": "Swelling",
            "percent": "100"
        },
        {
            "name": "mm",
            "percent": "1.1"
        },
        {
            "name": "Pain",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "6.9"
        },
        {
            "name": "Shivering",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4.5"
        },
        {
            "name": "Redness",
            "percent": "100"
        },
        {
            "name": "mm",
            "percent": "2.6"
        },
        {
            "name": "Swelling",
            "percent": "1"
        },
        {
            "name": "Pain",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "3.5"
        },
        {
            "name": "Redness",
            "percent": "100"
        },
        {
            "name": "mm",
            "percent": "3.1"
        },
        {
            "name": "Myalgia",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "2.8"
        },
        {
            "name": "Shivering",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "2.2"
        },
        {
            "name": "Headache",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "1.5"
        },
        {
            "name": "Swelling",
            "percent": "100"
        },
        {
            "name": "mm",
            "percent": "1.3"
        },
        {
            "name": "GI symptoms",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "1.2"
        },
        {
            "name": "years  Pain",
            "percent": "50"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "5-7"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Myalgia",
            "percent": "3-4"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Shivering",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Headache",
            "percent": "1-3"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Swelling",
            "percent": "0.1-2"
        },
        {
            "name": "mm",
            "percent": "100"
        },
        {
            "name": "Redness",
            "percent": "2"
        },
        {
            "name": "mm",
            "percent": "100"
        },
        {
            "name": "GI symptoms",
            "percent": "1-2"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Pain",
            "percent": "1"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "5-7"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Myalgia",
            "percent": "3-4"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Shivering",
            "percent": "2-4"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Headache",
            "percent": "1-3"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Swelling",
            "percent": "0.1-2"
        },
        {
            "name": "mm",
            "percent": "100"
        },
        {
            "name": "Redness",
            "percent": "2"
        },
        {
            "name": "mm",
            "percent": "100"
        },
        {
            "name": "GI symptoms",
            "percent": "1-2"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "years Fatigue",
            "percent": "1"
        },
        {
            "name": "Grade",
            "percent": "18-49"
        },
        {
            "name": "Myalgia",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "6-10"
        },
        {
            "name": "Shivering",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "4-8"
        },
        {
            "name": "Headache",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "1-6"
        },
        {
            "name": "Redness",
            "percent": "3"
        },
        {
            "name": "mm",
            "percent": "1-5"
        },
        {
            "name": "Fever",
            "percent": "100"
        },
        {
            "name": "Grade",
            "percent": "1-2"
        },
        {
            "name": "C",
            "percent": "3"
        },
        {
            "name": "F",
            "percent": "39.5"
        },
        {
            "name": "GI symptoms",
            "percent": "103"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "Swelling",
            "percent": "1"
        },
        {
            "name": "mm",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "1"
        },
        {
            "name": "Grade",
            "percent": "100"
        },
        {
            "name": "Myalgia",
            "percent": "0.1-1"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Shivering",
            "percent": "6-10"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Headache",
            "percent": "4-8"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Redness",
            "percent": "1-6"
        },
        {
            "name": "mm",
            "percent": "3"
        },
        {
            "name": "Fever",
            "percent": "1-5"
        },
        {
            "name": "Grade",
            "percent": "100"
        },
        {
            "name": "C",
            "percent": "1-2"
        },
        {
            "name": "F",
            "percent": "3"
        },
        {
            "name": "GI symptoms",
            "percent": "39.5"
        },
        {
            "name": "Grade",
            "percent": "103"
        },
        {
            "name": "Swelling",
            "percent": "1"
        },
        {
            "name": "mm",
            "percent": "1"
        },
        {
            "name": "Fever",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "1"
        },
        {
            "name": "GI symptoms",
            "percent": "100"
        },
        {
            "name": "Grade",
            "percent": "0.1-1"
        },
        {
            "name": "Pain",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "0.4"
        },
        {
            "name": "Fever",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "0.9"
        },
        {
            "name": "Fever",
            "percent": "3"
        },
        {
            "name": "grade",
            "percent": "0.5"
        },
        {
            "name": "years Fever",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "0.5"
        },
        {
            "name": "Fever",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "0.1"
        }
    ]
}